Moleculin Biotech (NASDAQ:MBRX) Stock Rating Upgraded by Wall Street Zen

Moleculin Biotech (NASDAQ:MBRX) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $22.00.

Moleculin Biotech Stock Down 0.4%

Shares of NASDAQ MBRX opened at $0.61 on Friday. The business’s 50 day moving average is $2.03 and its two-hundred day moving average is $2.48. The company has a market cap of $4.33 million, a P/E ratio of -0.03 and a beta of 1.84. Moleculin Biotech has a 12 month low of $0.16 and a 12 month high of $17.23.

Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.40) EPS for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.15. Sell-side analysts expect that Moleculin Biotech will post -3.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Moleculin Biotech

An institutional investor recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC bought a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech as of its most recent filing with the SEC. 15.52% of the stock is currently owned by institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.